STAT

In France, it’s illegal for consumers to order a DNA spit kit. Activists are fighting over lifting the ban

Under French law, having a direct-to-consumer genetic test can, technically speaking, put you at risk of being fined about $4,140.
Source: ERIC FEFERBERG/AFP via Getty Images

PARIS — From scanning her resume, you’d never guess Nathalie Jovanovic-Floricourt was an expert enabler of criminal activity. For years, she’d fretted over photo quality and page layout for publishing houses. Since 2007, she’s worked in communications for a bank — hardly a bastion of activist law-breakers. She lives in a quiet town an hour’s train ride away from Paris.

Then again, her underworld of choice is more socially acceptable than most: Jovanovic-Floricourt is a self-styled fixer for black-market genetic tests. She’s not a dealer. She doesn’t import spit-in-a-cup kits on anyone else’s behalf. She’s just tried out a bunch of different companies for herself — ordering them to an American package forwarding firm, say, if the manufacturer won’t ship directly to France — and helped others to do the same through talks, salons, books, and blog posts. Often, she says, fellow genealogists come to her with questions about their results.

“In doing these genetic ancestry tests, we’re risking a fine of 3,750 euros” — about $4,140 — “at least in theory,” she said one afternoon in late

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks